UbiVac, J&J deal

Johnson & Johnson’s Janssen Biotech Inc. unit partnered with UbiVac to develop preclinical and clinical versions of UbiVac’s DRibble immunotherapy technology to treat oral cancer. UbiVac will receive an upfront payment and is eligible for research, development and manufacturing milestones. Janssen will fund the research and have an option to license the technology. ...